138 related articles for article (PubMed ID: 84457)
1. [Principle of constructing polyvalent Pseudomonas aeruginosa vaccines].
Akatova NS
Zh Mikrobiol Epidemiol Immunobiol; 1979 Feb; (2):56-60. PubMed ID: 84457
[TBL] [Abstract][Full Text] [Related]
2. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines].
Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM
Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559
[TBL] [Abstract][Full Text] [Related]
3. [Protective action of a corpuscular polyvalent Pseudomonas aeruginosa vaccine against representative enterobacteria].
Vetkova LG; Antsiferova NG; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1985 Apr; (4):26-30. PubMed ID: 2409719
[TBL] [Abstract][Full Text] [Related]
4. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine].
Ttitova TI; Grigor'ev NI; Antsiferova NG; Radkevich SA; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392
[TBL] [Abstract][Full Text] [Related]
5. Protective mechanism of the immune response to a ribosomal vaccine from Pseudomonas aeruginosa. I. In vivo protection studies in compromised animal models.
Lieberman MM; Frank WJ
J Surg Res; 1988 Mar; 44(3):242-50. PubMed ID: 3125388
[TBL] [Abstract][Full Text] [Related]
6. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
[TBL] [Abstract][Full Text] [Related]
7. A new polyvalent pseudomonas vaccine.
Merle P; Robbel L; Hungerer KD
Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
[TBL] [Abstract][Full Text] [Related]
8. [Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia].
Vetkova LG; Zaĭtsev LG; Khasman EL; Radkevich SA; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):14-8. PubMed ID: 3085409
[TBL] [Abstract][Full Text] [Related]
9. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
Schiller B; Lysakowska E; Owczarska K
Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
[No Abstract] [Full Text] [Related]
10. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS
Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956
[No Abstract] [Full Text] [Related]
11. Pseudomonas aeruginosa antigens as potential vaccines.
Stanislavsky ES; Lam JS
FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
[TBL] [Abstract][Full Text] [Related]
12. [Cell-free Pseudomonas vaccine: its immunochemical characteristics and immunogenicity].
Bandman OA; Edvabnaia LS; Bulk VF; Zhvanetskaia MI; Mashilova GM
Zh Mikrobiol Epidemiol Immunobiol; 1987 Nov; (11):44-7. PubMed ID: 3124416
[TBL] [Abstract][Full Text] [Related]
13. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification.
Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A
Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473
[TBL] [Abstract][Full Text] [Related]
14. [Experimental immunological effectiveness and safety of pyoimmunogen vaccine against Pseudomonas aeruginosa infection].
Stanislavskiĭ ES; Ioo I; Severtsova MK; Mashilova GM; Boltutsiĭ LG
Zh Mikrobiol Epidemiol Immunobiol; 1982 May; (5):70-5. PubMed ID: 6808791
[TBL] [Abstract][Full Text] [Related]
15. Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection.
Gilleland HE; Gilleland LB; Staczek J; Harty RN; García-Sastre A; Palese P; Brennan FR; Hamilton WD; Bendahmane M; Beachy RN
FEMS Immunol Med Microbiol; 2000 Apr; 27(4):291-7. PubMed ID: 10727884
[TBL] [Abstract][Full Text] [Related]
16. Vaccines against Pseudomonas aeruginosa infection: 1. Experimental studies.
Stanislavsky ES; Joo I; Mashilova GM; Boolk VF; Boltutsy LG; Zakgeim DA; Severtśova MK; Yedvabnaya LS; Gladus MA; Fatkhinurova TI
Vaccine; 1985 Jun; 3(2):128-36. PubMed ID: 3929491
[TBL] [Abstract][Full Text] [Related]
17. [Experimental study of the protective activity of vaccines made from 7 Pseudomonas aeruginosa immunotypes].
Kholodkova EV; Fedotova IuM; Stanislavskiĭ ES
Zh Mikrobiol Epidemiol Immunobiol; 1987 Aug; (8):47-50. PubMed ID: 2446445
[TBL] [Abstract][Full Text] [Related]
18. [Production and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. IV. The effect of immunization with Pseudomonas aeruginosa vaccine on the immune status of volunteer donors].
Titova TI; Sidorova TN; Radkevich SA; Antsiferova NG; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1985 Aug; (8):80-4. PubMed ID: 3933225
[TBL] [Abstract][Full Text] [Related]
19. [Experimentally determined safety and immunological activity of vaccine based on antigens isolated from Pseudomonas aeruginosa in medium K-4].
Nuriddinova NR; Sheremet'ev NN; Ivanova LE; Garib FIu; Iskhakova KhI
Zh Mikrobiol Epidemiol Immunobiol; 2005; (3):57-60. PubMed ID: 16028515
[TBL] [Abstract][Full Text] [Related]
20. [Polish preparations for preventing and treating infections caused by Pseudomonas aeruginosa].
Schiller B; Buchowicz I; Lysakowska E; Sakiel S; Korbecki M
Zh Mikrobiol Epidemiol Immunobiol; 1985 Apr; (4):30-2. PubMed ID: 2409720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
